CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 951 enrolled
Drug / intervention
OraQuick® HIV Self-Testdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05020353
NCT05020353N/ACompleted

A Study to Evaluate the Accuracy, Usability and Readability of the OraQuick® HIV Self-Test Performed by Observed Intended Users in Canada

Unity Health Toronto·interventional·Posted Aug 25, 2021·Updated May 11, 2025

In Brief

A clinical study evaluating OraQuick® HIV Self-Test for HIV Testing and HIV Infections. Completed, enrolled 951 participants across 7 sites.

Detailed Summary

Oral fluid based HIV Self-testing (HIVST) provides another innovative and simple option to increase opportunities for HIV testing. At-home testing for HIV using oral fluid has been FDA approved and in use in the USA since 2012, and studies have also shown that interest and acceptability of HIVST with oral fluid is high in other global settings. However data for oral fluid based HIVST within key populations and those at high risk for HIV infection in Canada is limited. This study involves around 900 persons who are non-healthcare professionals and inexperienced in HIV self-testing (intended users) and are presenting at clinic sites across Canada for HIV testing. It will evaluate the accuracy (sensitivity and specificity), usability (persons performs test correctly) and readability (persons successfully interpret test results) of the OraQuick® HIV Self-Test when performed by persons representing intended users living in Canada. A final report of study results will be provided to the Test manufacturer for inclusion in the Health Canada license application process.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 25, 2021
Enrollment StartJun 21, 2022
Primary CompletionJul 4, 2023
Study CompletionMay 15, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.9 years ago

Interventions

OraQuick® HIV Self-Testdevice

OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.